Business

Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year

Some patients with obstructive sleep apnea and obesity who took the highest dose of Zepbound achieved “disease resolution” in the two trials.

Previous post Retail investors are having a pretty good year. Here’s why that could continue no matter what happens next.
Next post How a Florida traffic stop unraveled a multistate unemployment-benefit scam

More Stories